Equillium, Inc. announced interim results from its Type B portion (the second part) of the two-phase 1b EQUALISE study, investigating the drug itolizumab for the treatment of lupus nephritis (LN) (lupus-related kidney disease). So far, the study has yielded encouraging data.

Study participants with LN were administered the drug every two weeks during a 24-week period. At follow-up, 83% of participants achieved a complete or partial clinical response to the drug, with 67% reaching more than 80% reduction in urine protein levels, suggesting that the kidney function may be improved due to the absence of inflammation.

Researchers will continue to study the drug and further updates are expected in mid-2023. LN is a serious complication of lupus. Finding new and effective treatment options for LN is critically important. Continue to follow the Lupus Foundation of America for updates on itolizumab and learn more about medications used to treat lupus.

Read the announcement